EUVIMEDEUVIMED entdecken
Crossref

ACT I early feasibility study of the Voyager Ark vascular access device

John Ross iD, Stephen Hohmann, Alan Glowczwski, Justin Glowczwski, Anishaa Potnis, April Lovelady iD, Ashok Gowda

The Journal of Vascular Access · 2025

DOI: 10.1177/11297298241302887 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Vascular Access, 2025. Verfasst von John Ross und 6 weiteren Autor:innen. Beteiligte Einrichtung: Voyager Biomedical, Inc., Houston, TX, USA. Hauptthemen laut MEDLINE: Renal Dialysis, Arteriovenous Shunt, Surgical, Vascular Access Devices, Blood Vessel Prosthesis Implantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 7 Literaturangaben. Gefördert von: NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We report the 6-month outcomes of the Ark Cannulation Trial (ACT) I early feasibility study. This investigation examined the Ark as a potential innovative access tool for overcoming cannulation-related challenges and improving arteriovenous fistula (AVF) dependent hemodialysis through targeted cannulation.

Methods

During this first-in-human, interventional, prospective, single arm, single site investigation, 13 patients were treated. Cohort 1 included patients with existing fistulas meeting the criteria for Ark implantation at planned sites, including depth (4–15 mm), diameter (⩾4 mm), flow (⩾500 mL/min) and a poorly accessible cannulation zone. Cohort 2 included patients who underwent AVF creation and implantation of Arks at time of initial surgery. For both Cohorts, clinical need determined if one or two Arks were implanted. The primary endpoint was effective initial cannulation of the access site after Ark implantation. The secondary endpoint was continued access of the Ark cannulation zone for hemodialysis and evaluation of device or procedure-related adverse events collected for 6 months post-implantation. The exploratory endpoint evaluated the Ark implantation procedure.

Results

Of 13 patients, 2 were withdrawn prior to initial cannulation through the Ark—1 patient due to an exacerbated baseline condition and the other patient due to loss of follow-up. In the efficacy analysis, 11 of 13 treated patients demonstrated successful primary and secondary outcomes. Of the 11 treated patients who initiated cannulation through the Arks, 100% experienced successful primary and secondary outcomes. None of the patients experienced adverse events related to the Ark and surgeons had the necessary skills to implant Arks.

Conclusion

The results demonstrated the Ark could be used successfully in End-Stage Renal Disease (ESRD) patients undergoing hemodialysis three times a week. These results suggest preliminary safety and efficacy of the Ark as a promising cannulation tool for dialysis vascular access and warrant further exploration of long-term safety and effectiveness through a pivotal clinical study involving a larger population and extended follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal DialysisArteriovenous Shunt, SurgicalVascular Access DevicesBlood Vessel Prosthesis ImplantationHumansFeasibility StudiesProspective StudiesMaleTreatment OutcomeFemaleTime FactorsMiddle AgedAgedVascular PatencyProsthesis DesignAged, 80 and overAdult

Stichwörter der Autor:innen

Vascular accessVoyager Arkarteriovenous fistulacannulationhemodialysis

Autor:innen und Institutionen

  • Voyager Biomedical, Inc., Houston, TX, USA.
  • Vascular Surgery, Regional Medical Center, Orangeburg, SC, USA.
  • Vascular Surgery, Baylor, Scott, and White, Dallas, TX, USA.
  • Adjunct Professor at College of Veterinary Medicine, Texas A&M University, College Station, TX, USA.
  • Biotex Inc. Houston, TX, USA.
  • School of Engineering Medicine, Texas A&M University, Houston, TX, USA.

ORCID-Profile: John Ross, April Lovelady

Förderung

  • NIH

Zitieren

APA

Ross, J., Hohmann, S., Glowczwski, A., Glowczwski, J., Potnis, A., Lovelady, A., & Gowda, A. (2025). ACT I early feasibility study of the Voyager Ark vascular access device. The Journal of Vascular Access. https://doi.org/10.1177/11297298241302887

Vancouver

Ross J, Hohmann S, Glowczwski A, Glowczwski J, Potnis A, Lovelady A, et al. ACT I early feasibility study of the Voyager Ark vascular access device. The Journal of Vascular Access. 2025. doi:10.1177/11297298241302887

BibTeX
@article{Ross2025,
  author = {Ross, John and Hohmann, Stephen and Glowczwski, Alan and Glowczwski, Justin and Potnis, Anishaa and Lovelady, April and Gowda, Ashok},
  title = {ACT I early feasibility study of the Voyager Ark vascular access device},
  journal = {The Journal of Vascular Access},
  year = {2025},
  doi = {10.1177/11297298241302887}
}
Kostenlos starten →